Revolutionizing exosome science to heal from within
Revolutionizing exosome science to heal from within
“For decades, the promise of cell-based therapies remained just that – a promise. At RION, we are turning that promise into reality by leveraging the remarkable properties of exosomes. This is more than just innovation; it’s a revolution in regenerative medicine.”
– Dr. Atta Behfar, Co-founder, RION
“For decades, the promise of cell-based therapies remained just that – a promise. At RION, we are turning that promise into reality by leveraging the remarkable properties of exosomes. This is more than just innovation; it’s a revolution in regenerative medicine.”
– Dr. Atta Behfar, Co-founder, RION
EXOSOME REVOLUTION:
We are Transforming Regenerative Medicine
RION, established out of the Mayo Clinic Employee Entrepreneurial Program in 2017, is a clinical-stage regenerative medicine company based in Rochester, MN. With a commitment to changing the approach to regenerative medicine, the company has isolated from platelets a unique exosome phenotype that is the key to tissue regeneration in the body called Purified Exosome Product or PEP™ which was discovered at the Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program. RION has advanced this technology by building a proprietary platform focused on defining PEP™’s mode of action, scaled exosome manufacturing and therapeutic applications.
EXOSOME REVOLUTION:
We are Transforming Regenerative Medicine
RION, established out of the Mayo Clinic Employee Entrepreneurial Program in 2017, is a clinical-stage regenerative medicine company based in Rochester, MN. With a commitment to changing the approach to regenerative medicine, the company has isolated from platelets a unique exosome phenotype that is the key to tissue regeneration in the body called Purified Exosome Product or PEP™ which was discovered at the Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program. RION has advanced this technology by building a proprietary platform focused on defining PEP™’s mode of action, scaled exosome manufacturing and therapeutic applications.
THE APPROACH
EXOSOMES AND PLATELETS
EXOSOMES
Exosomes are nanoscale extracellular vesicles, secreted by cells, that act as carriers of biological messages. These messages, composed of proteins, nucleic acids, and lipids, are transported from their cell of origin to other cells, orchestrating a multitude of processes that underpin health, disease, and the regenerative capabilities of the body.
THE APPROACH
EXOSOMES AND PLATELETS
EXOSOMES
Exosomes are nanoscale extracellular vesicles, secreted by cells, that act as carriers of biological messages. These messages, composed of proteins, nucleic acids, and lipids, are transported from their cell of origin to other cells, orchestrating a multitude of processes that underpin health, disease, and the regenerative capabilities of the body.
PLATELETS
RION harnesses the unique regenerative properties of platelets, an ideal source of regenerative exosomes, due to their natural role in healing and regeneration.
Unlike other sources, platelet-derived exosomes are inherently designed to promote tissue repair, making them a superior choice for therapeutic applications.
Platelets are natural, sustainable, and a cost-effective source of regenerative exosomes.
PLATELETS
RION harnesses the unique regenerative properties of platelets, an ideal source of regenerative exosomes, due to their natural role in healing and regeneration.
Unlike other sources, platelet-derived exosomes are inherently designed to promote tissue repair, making them a superior choice for therapeutic applications.
Platelets are natural, sustainable, and a cost-effective source of regenerative exosomes.
SCALING EXOSOME INNOVATION:
Our Breakthrough Manufacturing Process Produces PEP™ (Purified Exosome Product™)
RION has developed a proprietary process that isolates regenerative exosomes from platelets and enables their mass production, addressing the significant industry challenge of scalability. This breakthrough not only amplifies the potential for extensive therapeutic application but also represents a substantial advance in the commercial viability of exosome-based treatments. PEP™ is RION’s innovative Drug Substance containing trillions of platelet-derived regenerative exosomes.
SCALING EXOSOME INNOVATION:
Our Breakthrough Manufacturing Process Produces PEP™ (Purified Exosome Product™)
RION has developed a proprietary process that isolates regenerative exosomes from platelets and enables their mass production, addressing the significant industry challenge of scalability. This breakthrough not only amplifies the potential for extensive therapeutic application but also represents a substantial advance in the commercial viability of exosome-based treatments. PEP™ is RION’s innovative Drug Substance containing trillions of platelet-derived regenerative exosomes.
Regenerative Exosomes in a Bottle
Purified Exosome Product™ (PEP™)
The result of RION’s proprietary manufacturing process is a novel ingredient called Purified Exosome Product (PEP™). Depending on the clinical application each vial of PEP™ can be manufactured to contain up to 2 trillion regenerative exosomes. PEP™ is packaged as a lyophilized powder that is stored at room temperature with 24 months of shelf life. Thus, PEP™ can be easily reconstituted in water or saline to deliver the regenerative potential of exosomes to tissues in the body.
Properties of PEP™
RION’s research shows that PEP™ has the ability to regenerate many types of tissues – skin, heart, muscle, tendon, lung, nerve, vaginal mucosa. (data on file at RION)
RION has proven that PEP™ can be administered through multiple routes of administration, including topical, intra-articular, IV, IM, and nebulizer applications, to target different diseases and body areas.
Regenerative Exosomes in a Bottle
Purified Exosome Product™ (PEP™)
The result of RION’s proprietary manufacturing process is a novel ingredient called Purified Exosome Product (PEP™). Depending on the clinical application each vial of PEP™ can be manufactured to contain up to 2 trillion regenerative exosomes. PEP™ is packaged as a lyophilized powder that is stored at room temperature with 24 months of shelf life. Thus, PEP™ can be easily reconstituted in water or saline to deliver the regenerative potential of exosomes to tissues in the body.
Properties of PEP™
RION’s research shows that PEP™ has the ability to regenerate many types of tissues – skin, heart, muscle, tendon, lung, nerve, vaginal mucosa. (data on file at RION)
RION has proven that PEP™ can be administered through multiple routes of administration, including topical, intra-articular, IV, IM, and nebulizer applications, to target different diseases and body areas.
THE FUTURE OF EXOSOMES
RION’s Drug Delivery Platform
- Massive scaling of manufacturing allows exosomes to become the delivery vehicle
- RION has developed a patent protected process to deliver mRNA, siRNA, DNA and small molecules
- Platelet-derived exosomes significantly improve targeting and drug delivery efficiency versus Lipid Nanoparticles
PEP™
Rion’s Regenerative Exosome
Release
Release of Cargo (proteins, RNA, DNA)
Replace
Cargo Replacement (can be any drug)
Result
Drug Encapsulated Exosome
RION’s Next-Gen Platelet-Derived Exosome Technology
- Our R&D team is spearheading the development of next-generation exosome technologies designed to precisely deliver therapeutic payloads.
- We encapsulate small molecule drugs, proteins, DNA, or RNA within our proprietary PEP™ technology, enhancing bioavailability and uptake within the body.
- The innovative PEP™ lipid bilayer surrounds and protects the therapeutic cargo, ensuring:Enhanced Biodistribution and Uptake: PEP™ guides the cargo to its target, maximizing its therapeutic effect.
- Reduced Systemic Toxicities: The protective layer minimizes unintended side effects on the body.
“Exosome therapy becomes the delivery vehicle.” – Andre Terzic, MD, PhD